TransCode Therapeutics (RNAZ) Competitors $7.56 -0.49 (-6.09%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$7.44 -0.12 (-1.59%) As of 01/31/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNAZ vs. MEIP, MIRA, FNCH, GOVX, BTAI, CDIO, CLDI, OKUR, BCTX, and IPAShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include MEI Pharma (MEIP), MIRA Pharmaceuticals (MIRA), Finch Therapeutics Group (FNCH), GeoVax Labs (GOVX), BioXcel Therapeutics (BTAI), Cardio Diagnostics (CDIO), Calidi Biotherapeutics (CLDI), OnKure Therapeutics (OKUR), BriaCell Therapeutics (BCTX), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. MEI Pharma MIRA Pharmaceuticals Finch Therapeutics Group GeoVax Labs BioXcel Therapeutics Cardio Diagnostics Calidi Biotherapeutics OnKure Therapeutics BriaCell Therapeutics ImmunoPrecise Antibodies TransCode Therapeutics (NASDAQ:RNAZ) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment. Does the MarketBeat Community favor RNAZ or MEIP? MEI Pharma received 395 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 92.86% of users gave TransCode Therapeutics an outperform vote while only 62.48% of users gave MEI Pharma an outperform vote. CompanyUnderperformOutperformTransCode TherapeuticsOutperform Votes1392.86% Underperform Votes17.14%MEI PharmaOutperform Votes40862.48% Underperform Votes24537.52% Which has higher valuation & earnings, RNAZ or MEIP? MEI Pharma has higher revenue and earnings than TransCode Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$18.55MN/AN/AMEI Pharma$65.30M0.29$17.78M-$6.99-0.41 Do insiders and institutionals hold more shares of RNAZ or MEIP? 52.4% of MEI Pharma shares are held by institutional investors. 2.8% of TransCode Therapeutics shares are held by company insiders. Comparatively, 3.1% of MEI Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is RNAZ or MEIP more profitable? MEI Pharma's return on equity of -84.80% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -649.03% -281.34% MEI Pharma N/A -84.80%-65.24% Which has more volatility and risk, RNAZ or MEIP? TransCode Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Does the media favor RNAZ or MEIP? In the previous week, TransCode Therapeutics had 10 more articles in the media than MEI Pharma. MarketBeat recorded 12 mentions for TransCode Therapeutics and 2 mentions for MEI Pharma. MEI Pharma's average media sentiment score of 1.43 beat TransCode Therapeutics' score of 0.19 indicating that MEI Pharma is being referred to more favorably in the news media. Company Overall Sentiment TransCode Therapeutics Neutral MEI Pharma Positive Do analysts prefer RNAZ or MEIP? TransCode Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 164.55%. MEI Pharma has a consensus target price of $7.00, suggesting a potential upside of 145.61%. Given TransCode Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe TransCode Therapeutics is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MEI Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryMEI Pharma beats TransCode Therapeutics on 9 of the 14 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.85M$6.85B$5.57B$9.11BDividend YieldN/A2.90%5.32%3.99%P/E RatioN/A9.7489.4218.28Price / SalesN/A301.931,253.4080.65Price / CashN/A73.5045.9637.70Price / Book0.095.275.124.70Net Income-$18.55M$136.98M$111.33M$224.47M7 Day Performance7.39%-0.73%2.33%-0.20%1 Month Performance124.33%0.16%3.19%0.57%1 Year Performance-98.98%7.59%24.63%20.29% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics3.123 of 5 stars$7.56-6.1%$20.00+164.6%-99.0%$5.85MN/A0.009News CoverageGap DownMEIPMEI Pharma4.5394 of 5 stars$2.82-1.1%$7.00+148.2%-36.7%$18.78M$65.30M-0.40100Short Interest ↓Positive NewsGap DownMIRAMIRA Pharmaceuticals2.4976 of 5 stars$1.12-1.8%$14.00+1,150.0%+27.7%$18.55MN/A-2.002Positive NewsFNCHFinch Therapeutics GroupN/A$11.50+4.5%N/A+309.2%$18.47M$110,000.00-1.30190High Trading VolumeGOVXGeoVax Labs2.674 of 5 stars$1.94-6.3%$14.20+632.0%-43.7%$18.31M$80,000.000.0010Analyst ForecastShort Interest ↑Gap UpBTAIBioXcel Therapeutics4.2495 of 5 stars$0.37+7.5%$2.81+669.3%-89.9%$18.15M$1.38M-0.1790Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageCDIOCardio Diagnostics2.9565 of 5 stars$0.44-4.4%$2.00+355.6%-79.9%$17.75M$20,000.000.001Short Interest ↓CLDICalidi Biotherapeutics2.4632 of 5 stars$0.66-11.0%$16.67+2,424.9%N/A$17.47M$50,000.000.0038News CoverageOKUROnKure Therapeutics3.3204 of 5 stars$5.19-8.3%$36.00+593.6%N/A$17.34MN/A-0.43N/ANews CoverageGap DownBCTXBriaCell Therapeutics2.8091 of 5 stars$0.39-2.6%$15.00+3,779.0%-91.9%$17.09MN/A-0.438IPAImmunoPrecise Antibodies3.4075 of 5 stars$0.54-6.3%$5.00+825.9%-74.3%$16.77M$18.16M-0.6980Gap Up Related Companies and Tools Related Companies MEI Pharma Competitors MIRA Pharmaceuticals Competitors Finch Therapeutics Group Competitors GeoVax Labs Competitors BioXcel Therapeutics Competitors Cardio Diagnostics Competitors Calidi Biotherapeutics Competitors OnKure Therapeutics Competitors BriaCell Therapeutics Competitors ImmunoPrecise Antibodies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNAZ) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
